Prognostic factors and survival in metastatic breast cancer: A single institution experience

Khanfir, Afef; Lahiani, Faiez; Bouzguenda, Racem; Ayedi, Ines; Daoud, J.; Frikha, M.

doi:10.1016/j.rpor.2013.01.001

Cited by 57 publications

(42 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[4][5][6] In our patient population, overall survival after the diagnosis of liver metastases was 18 months which was in line with the results of more recent studies. 12 We revealed that early stage disease at diagnosis, non TNBC disease and presence of local hepatic treatment were long survival after hepatic metastasis by multivariate analysis (Table 4). However age at diagnosis, adjuvant chemotherapy, and adjuvant endocrine therapy were found to have no influence on survival in patients after the development of hepatic metastases.…”

Section: Discussionmentioning

confidence: 89%

“…It has been reported that nearly 30% of breast cancer patients will develop liver metastases along the duration of their disease. 1-2 Liver metastases usually develop in the terminal stage of breast Hepatic with brain 13 (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22) International Journal of Hematology and Oncology cancer, and are often accompanied by extrahepatic metastases. Isolated liver metastases are very rare (4%-5%).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Factors In Breast Cancer Patients With Hepatic Metastases: Impact Of Molecular Subtype And Local Hepatic Treatment

Ateş¹

2016

UHOD

View full text Add to dashboard Cite

Liver metastases usually develop in the terminal stage of breast cancer (BC), and often accompany with extrahepatic metastases. The prognosis of hepatic metastases (HM) in BC patient is poorer compared to bone and soft tissue metastases. In this study, we aimed to analyze some clinico-pathological prognostic factors in patients with HM. A total of 4300 follow-up records of breast cancer patients diagnosed and treated at Hacettepe University Cancer Institute between January 2000 and July 2015 were retrospectively analyzed. Total of 312 BC patients with HM were enrolled to study. Patients with HM at diagnosis and the patients who developed metastases during the follow-up were included. Total of 50 (16%) patients have HM as the first site of metastasis. While isolated HM were just seen in 36 (11%) patients, most of the patients had hepatic as well as bone metastases (n=148, 47%). Median interval from initial diagnosis to HM was 40.5 (5-262) months. Low grade (grade 1-2) tumors were associated with longer disease free interval to liver metastases by multivariate analysis. Overall survival after HM in whole group was 18 months. Multivariate analysis revealed statistically significant association between long survival and non-triple negative molecular subtype, lower stage disease at diagnosis and application of local hepatic treatment. Developments in systemic and targeted therapy, as well as local hepatic therapies may enhance outcomes of patient with hepatic metastases.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Prognostic Factors In Breast Cancer Patients With Hepatic Metastases: Impact Of Molecular Subtype And Local Hepatic Treatment

Ateş¹

2016

UHOD

View full text Add to dashboard Cite

show abstract

“…Surgical treatment modalities have extended from mastectomy to breast conservation therapy. Adjuvant radiotherapy has shown long term survival benefit in these patients [1,4,5,6,7]. Post mastectomy radiotherapy has a limited role in patients with four or more metastatic axillary nodes, large primary tumours and chest wall invasion [4].…”

Section: Discussionmentioning

confidence: 99%

A case of metaplastic breast carcinoma - an aggressive malignant tumour

Sivamayuran

Raviraj

2017

J. Postgrad. Inst. Med.

View full text Add to dashboard Cite

“…Breast cancer, one of the most prevalent cancers through the world, is the main cause of cancer death among the women (1). According to recent studies about 40% of all breast cancer patients are at high risk of recurrence.…”

Section: Introductionmentioning

confidence: 99%

The Effect of Duloxetine on Tau Protein and Migration in Breast Cancer Cell Line

et al. 2017

View full text Add to dashboard Cite

Background: Metastasis is one the most important causes of death among the patients diagnosed with breast cancer. Tau protein is a cytoskeletal protein which competes with paclitaxel and attenuates its effects. So increased tau protein may promote metastasis progression. Duloxetine is an antidepressant inhibiting serotonin, norepinephrine reuptake. In this study we tried to investigate the effects of duloxetine in tau gene expression in breast cancer cell line.

show abstract

Prognostic factors and survival in metastatic breast cancer: A single institution experience

Cited by 57 publications

References 33 publications

Prognostic Factors In Breast Cancer Patients With Hepatic Metastases: Impact Of Molecular Subtype And Local Hepatic Treatment

Prognostic Factors In Breast Cancer Patients With Hepatic Metastases: Impact Of Molecular Subtype And Local Hepatic Treatment

A case of metaplastic breast carcinoma - an aggressive malignant tumour

The Effect of Duloxetine on Tau Protein and Migration in Breast Cancer Cell Line

Contact Info

Product

Resources

About